Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization
Abstract
Background: To investigate the safety and efficacy of prophylactic use of commercially available intravitreal moxifloxacin 0.5% (Vigamox) at the time of intravitreal anti-VEGF injection against post-injection infectious endophthalmitis.
Patients and methods: A prospective interventional randomized controlled trial including eyes with cystoid macular edema or macular neovascularization planned to receive intravitreal anti-VEGF therapy. Eyes were randomly assigned to either day A or day B for intravitreal injection procedure; eyes in day A received simultaneous intravitreal anti-VEGF and moxifloxacin (study group), while eyes in day B received intravitreal anti-VEGF only (control group). The presence of postoperative toxic reactions and endophthalmitis rates was assessed together with change in BCVA & retinal in both groups.
Results: A total of 1352 intravitreal injection procedures were done in study group and 1487 in control group. Endophthalmitis was rare across both groups, 0 case in the study group and two cases (0.2%) in the control group which was statistically insignificant (P = 0.502). Reduction in CME was comparable in both groups, (MD = -228.17 μm) in the study group, (MD = -221.28 μm) in the control group (P = 0.044). Similar Improvement of BCVA in both groups with a difference of -0.56 in the study group and - 0.54 in the control group (P = 0.151). No toxic AC reactions or retinal toxicity was observed in the study group confirmed by similar postoperative…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.